Tyrosine kinase inhibitors
The present disclosure provides compounds such as pyrazolpyrimidine compounds, and pharmaceutically acceptable salts thereof, that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
1. An (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof wherein the compound is 4-amino-2-(2-((4-amino-3-(2-fluoro-4-(3-fluorophenoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
4-amino-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methyl-4-morpholinopent-2-enenitrile having the structure:
4-amino-2-(2-((4-amino-3-(4-(2,3-difluorophenoxy)-2-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
or an (E) or (Z) isomer, or a mixture of (E) and (Z) isomers of any of the foregoing.
2. The (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof of claim 1 wherein the compound is (R)-4-amino-2-(2-((4-amino-3-(2-fluoro-4-(3-fluorophenoxy)-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
or an (E) or (Z) isomer, or a mixture of (E) and (Z) isomers thereof;
or a pharmaceutically acceptable salt of any of the foregoing.
3. The (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof of claim 1 wherein the compound is (R)-4-amino-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
or an (E) or (Z) isomer, or a mixture of (E) and (Z) isomers thereof; or
a pharmaceutically acceptable salt of any of the foregoing.
4. The (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof of claim 1 wherein the compound is (R,E)-4-amino-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
or a pharmaceutically acceptable salt thereof.
5. The (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof of claim 1 wherein the compound is (R,Z)-4-amino-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
or a pharmaceutically acceptable salt thereof.
6. The (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof of claim 1 wherein the compound is (S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-pyrrolidine-1-carbonyl)-4-methyl-4-morpholinopent-2-enenitrile having the structure:
or an (E) or (Z) isomer, or a mixture of (E) and (Z) isomers thereof; or
a pharmaceutically acceptable salt of any of the foregoing.
7. The (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof of claim 1 wherein the compound is (S,E)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-pyrrolidine-1-carbonyl)-4-methyl-4-morpholinopent-2-enenitrile having the structure:
or a pharmaceutically acceptable salt thereof.
8. The (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof of claim 1 wherein the compound is (S,Z)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-pyrrolidine-1-carbonyl)-4-methyl-4-morpholinopent-2-enenitrile having the structure:
or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising an (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers or an (E) or (Z) isomer, or a mixture of (E) and (Z) isomers of a compound or a pharmaceutically acceptable salt thereof of claim 1 and a pharmaceutically acceptable excipient.
10. The pharmaceutical composition of claim 9 wherein the (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof is (R)-4-amino-2-(2-((4-amino-3-(2-fluoro-4-(3-fluorophenoxy)-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
or an (E) or (Z) isomer, or a mixture of (E) and (Z) isomers thereof;
or a pharmaceutically acceptable salt of any of the foregoing.
11. The pharmaceutical composition of claim 9 wherein the (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof is (R)-4-amino-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
or an (E) or (Z) isomer, or a mixture of (E) and (Z) isomers thereof; or a pharmaceutically acceptable salt thereof of any of the foregoing.
12. The pharmaceutical composition of claim 9 wherein the (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof is (R,E)-4-amino-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
or a pharmaceutically acceptable salt thereof.
13. The pharmaceutical composition of claim 9 wherein the (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof is (R,Z)-4-amino-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)pyrrolidine-1-carbonyl)-4-methylpent-2-enenitrile having the structure:
or a pharmaceutically acceptable salt thereof.
14. The pharmaceutical composition of claim 9 wherein the (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof is (S)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-pyrrolidine-1-carbonyl)-4-methyl-4-morpholinopent-2-enenitrile having the structure:
or an (E) or (Z) isomer, or a mixture of (E) and (Z) isomers; or a pharmaceutically acceptable salt of any of the foregoing.
15. The pharmaceutical composition of claim 9 wherein the (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof is (S,E)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-pyrrolidine-1-carbonyl)-4-methyl-4-morpholinopent-2-enenitrile having the structure:
or a pharmaceutically acceptable salt thereof.
16. The pharmaceutical composition of claim 9 wherein the (R) isomer, (S) isomer, or a mixture of (R) and (S) isomers of a compound or a pharmaceutically acceptable salt thereof is (S,Z)-2-(2-((4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-pyrrolidine-1-carbonyl)-4-methyl-4-morpholinopent-2-enenitrile having the structure:
or a pharmaceutically acceptable salt thereof.